Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients
Uložené v:
| Názov: | Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients |
|---|---|
| Autori: | Chaumont, Hugo, Meppiel, E., Roze, E., Tressières, B., de Broucker, T., Lannuzel, A. |
| Prispievatelia: | Sorbonne Université, Gestionnaire HAL 9 - Cécile |
| Zdroj: | Rev Neurol (Paris) |
| Informácie o vydavateľovi: | Elsevier BV, 2022. |
| Rok vydania: | 2022 |
| Predmety: | SARS-CoV-2, COVID-19, COVID-19 Neurological manifestation NeuroCOVID Post-COVID Syndrome Long-term outcomes, 3. Good health, Neurological manifestation, 03 medical and health sciences, 0302 clinical medicine, Post-COVID Syndrome, Quality of Life, Humans, NeuroCOVID, Original Article, Long-term outcomes, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Nervous System Diseases, Follow-Up Studies |
| Popis: | Long-term outcomes after neurological manifestations due to COVID-19 are poorly known. The aim of our study was to evaluate the functional outcome and identify the risk factors of neurologic sequelae after COVID-19 associated with neurological manifestations (NeuroCOVID).We conducted a multi-center observational study six months after the acute neurological symptoms in patients from the French NeuroCOVID hospital-based registry.We obtained data on 60 patients. NeuroCOVID had a negative impact on the quality of life (QoL) of 49% of patients. Age was a predictor of residual QoL impairment (OR: 1.06, 95% CI: 1.01-1.13, p=0.026). At six months, a significant residual disability was found in 51.7% of patients, and impaired cognition in 68.9% of cases. The main persistent neuropsychiatric manifestations were a persistent smell/taste disorder in 45% of patients, memory complaints in 34% of patients, anxiety or depression in 32% of patients.NeuroCOVID likely carries a high risk of long-term neuropsychiatric disability. Long-term care and special attention should be given to COVID-19 patients, especially if they had neurological manifestations during acute infection. |
| Druh dokumentu: | Article Other literature type |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 0035-3787 |
| DOI: | 10.1016/j.neurol.2021.12.008 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/35000793 https://hal.sorbonne-universite.fr/hal-04573166v1 https://hal.sorbonne-universite.fr/hal-04573166v1/document https://doi.org/10.1016/j.neurol.2021.12.008 |
| Rights: | Elsevier TDM |
| Prístupové číslo: | edsair.doi.dedup.....6099786012098d0f4bcc5aee45c423ed |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Long-term outcomes after neurological manifestations due to COVID-19 are poorly known. The aim of our study was to evaluate the functional outcome and identify the risk factors of neurologic sequelae after COVID-19 associated with neurological manifestations (NeuroCOVID).We conducted a multi-center observational study six months after the acute neurological symptoms in patients from the French NeuroCOVID hospital-based registry.We obtained data on 60 patients. NeuroCOVID had a negative impact on the quality of life (QoL) of 49% of patients. Age was a predictor of residual QoL impairment (OR: 1.06, 95% CI: 1.01-1.13, p=0.026). At six months, a significant residual disability was found in 51.7% of patients, and impaired cognition in 68.9% of cases. The main persistent neuropsychiatric manifestations were a persistent smell/taste disorder in 45% of patients, memory complaints in 34% of patients, anxiety or depression in 32% of patients.NeuroCOVID likely carries a high risk of long-term neuropsychiatric disability. Long-term care and special attention should be given to COVID-19 patients, especially if they had neurological manifestations during acute infection. |
|---|---|
| ISSN: | 00353787 |
| DOI: | 10.1016/j.neurol.2021.12.008 |